About Dylan Sammut
Dylan joined Irving Levin in October 2018 as a Research and Editorial Associate and is responsible for reporting on mergers and acquisitions in the healthcare sector. He graduated from Alfred University in May 2014 with a degree in English and Political Science. He currently lives in Bridgeport, CT with his fiancé and his overweight cat, Kimba, and in his free time he plays video games, reads, writes, and hikes on the weekends all year around.
by Dylan Sammut | Dec 29, 2020 8:10 am | Physician Medical Groups, Private Equity
The private equity-backed EyeSouth Partners is closing 2020 on a strong note. With the support of Shore Capital Partners, EyeSouth Partners added Eye Center of Texas (ECT), which employs 14 physicians across six primary clinical locations in the greater Houston area... Read More »
by Dylan Sammut | Dec 29, 2020 8:09 am | Pharmaceuticals
The France-based pharmaceutical company Servier is back with a new deal, adding Agios Pharmaceuticals, Inc.‘s (NASDAQ: AGIO) oncology portfolio for $1.8 billion upfront in cash. The portfolio consists of Agios’ commercial, clinical and research-stage oncology product... Read More »
by Dylan Sammut | Dec 21, 2020 3:59 pm | eHealth
After no updates in the M&A market for more than five years, according to results in our Healthcare Deal Database, Cerner Corporation (NASDAQ: CERN) is back with a new deal. The digital health company announced it is acquiring Kantar Health for $375 million in... Read More »
by Dylan Sammut | Dec 21, 2020 3:45 pm | Behavioral Health Care
BayMark Health Services announced a trio of deals last week alone, doubling its transaction count for 2020, based on results from Healthcare Deals Database. With the backing of private equity firm Webster Equity Partners, the nationwide behavioral health provider... Read More »
by Dylan Sammut | Dec 21, 2020 3:00 pm | Medical Devices
The medical device giant Royal Philips (NYSE: PHG) is back with a new deal, adding BioTelemetry, Inc. (NYSE: BEAT). The deal is valued at $2.8 billion, consisting of $72.00 per share in cash, or a 16.5% premium to BEAT’s closing price on December 17, 2020.... Read More »